m+Medelevator.RU
← Поиск публикаций
BMC cancer · 2026

Integrated in vivo and in vitro experiments with multi-omics analysis reveal SPP1 drives pancreatic cancer progression.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ke Mujing

Аннотация

OBJECTIVE: To investigate the expression pattern of SPP1 in pancreatic cancer and its role in the tumor immune microenvironment, with functional validation by in vivo and in vitro experiments. METHODS: Bioinformatics analyses were performed using TCGA and CCLE databases to assess SPP1 expression, prognostic value, and immune correlations in pan-cancer and pancreatic cancer. Single-cell transcriptomic and CellChat analyses were used to explore cell communication and immune microenvironment characteristics. An orthotopic pancreatic cancer mouse model was established, and in vivo and in vitro experiments including flow cytometry, Western blot, co-immunoprecipitation (Co-IP), and in vivo ubiquitination assays were conducted to validate the immunoregulatory role of tumor-derived SPP1. RESULTS: SPP1 was highly expressed in pancreatic cancer and associated with poor prognosis, elevated immunosuppressive microenvironment scores, and increased M2 macrophage infiltration. Single-cell and cell communication analyses indicated that SPP1 was mainly derived from macrophages and ductal epithelial cells, contributing to immune-regulatory signaling. Functional experiments confirmed that SPP1 promoted M2 macrophage polarization, enhanced immunosuppressive cytokine expression, and facilitated tumor progression through immune microenvironment remodeling. CONCLUSION: SPP1 plays a critical role in regulating macrophage polarization and shaping an immunosuppressive tumor microenvironment in pancreatic cancer, suggesting its potential as a therapeutic target.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты